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Abstract: MiRNAs play a relevant role in PC (prostate cancer) by the regulation in the expression of
several pathways’ AR (androgen receptor), cellular cycle, apoptosis, MET (mesenchymal epithelium
transition), or metastasis. Here, we report the role of several miRNAs’ expression patterns, such
as miR-miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, miR-592, miR-141, miR-375, and miR-130b,
with relevance in processes like cell proliferation and MET. Using Trizol® extraction protocol and
TaqMan™ specific probes for amplification, we performed miRNAs’ analysis of 159 PC fresh tissues
and 60 plasmas from peripheral blood samples. We had clinical data from all samples including PSA,
Gleason, TNM, and D’Amico risk. Moreover, a bioinformatic analysis in TCGA (The Cancer Genome
Atlas) was included to analyze the effect of the most relevant miRNAs according to aggressiveness
in an extensive cohort (n = 531). We found that miR-210-3p, miR-23c, miR-592, and miR-93-5p are
the most suitable biomarkers for PC aggressiveness and diagnosis, respectively. In fact, according
with our results, miR93-5p seems the most promising non-invasive biomarker for PC. To sum up,
miR-210-3p, miR-23c, miR-592, and miR93-5p miRNAs are suggested to be potential biomarkers
for PC risk stratification that could be included in non-invasive strategies such as liquid biopsy in
precision medicine for PC management.
Keywords: aggressiveness; biomarkers; bioinformatic; precision medicine; prostate cancer
1. Introduction
Current medicine is focused on precision medicine, with the aim of providing better
management and treatment of patients in several diseases like cancer. One of the main
aspects of precision medicine is to provide optimal biomarkers, to offer more accurate
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strategies for disease detection, diagnosis, prognosis, prediction of response to intervention,
and disease monitoring.
PC is one of the most prevalent (incidence of 37.5 per 100,000) tumors among men in
the world after lung cancer and the second most frequent cause of cancer-related death
(375,000 deaths worldwide) [1]. It also accounts for around the 20% of newly diagnosed
cancers, according to 2020 cancer statistics [2]. However, there are not many biomarkers
used into clinical practice. Liquid biopsy in cancer has gained momentum in clinical
research and it is experiencing a boom for various applications. For instance, exosome-
based biomarkers have quickly become adopted in the clinical arena and the first PC
exosome RNA-based test has already helped >50,000 patients in decision processes. As
a result, it is now included in the National Comprehensive Cancer Network (NCCN)
guidelines for early PC detection [3]. Moreover, recent studies have evaluated the role of a
circular RNA, known as circANKS1B, as a potential prognostic biomarker and therapeutic
target for PC. This circANKS1B has been suggested to act as a sponge for miR-152-3p,
promoting PC progression by upregulating TGF-α expression [4]. Others include the role
of miR-144 as a potential biomarker for predicting PC progression, by its interaction with
EZH2, reducing cell viability and promoting cell apoptosis [5], or the role described for
miR-145-5p in PC metastasis by binding TOP2A, which is indicated as a useful biomarker
for metastatic PC detection [2]. However, there are also data including miR-320a as a
valuable biomarker that can be used in early diagnosis of PC [6].
We focused, in the present work, on several miRNAs based on carcinogenesis or
tumor aggressiveness. In this regards, miR-93-5p, in combination with other miRNAs
(miR-17-5p, miR-20a-5p, miR-92a-3p), has been appointed as a potential signature in PC,
by the regulation of relevant genes such as E2F2, RRM2, and PKMYT1 [7]. Additionally,
miR-23c has been recently indicated as a biomarker for predicting recurrence in PC, by
its critical role on RGN (Regucalcin) gene. RGN promotes dormancy in PC [8]. Moreover,
miR-23c has been described as an inhibitor of cell proliferation and a promoter of apoptosis
by attenuating ERBB2IP (erbb2 interacting protein) [9].
In the case of miR-210-3p, it was previously included as a potentially non-invasive
biomarker related to diagnosis and treatment management in clear cell renal cell carci-
noma [10]. In PC, several results indicated that an up-regulation of miR-210-3p activates
NF-κB signaling pathway, which is related to bone metastasis in PC, or even targets FGFRL1,
which promotes lung cancer metastasis [11,12]. Moreover, there are also reports about
miR-210-3p-EphrinA3-PI3K/AKT signaling axis and its role in oral squamous cell carci-
noma progress and treatment [13]. Recent data exposed by Ruiz-Plazas et al. reinforced the
relevant role of miRNAs as biomarkers in PC. Ruiz-Plazas et al. discovered, in 97 semen
samples from PC patients, the efficiency of exo-oncomiR-221-3p, miR-222-3p, and TWEAK
as biomarkers for classification of aggressive PC patients (with 85.7% specificity and 76.9%
sensitivity) [14]. However, miR-221-3p is also related to breast cancer as a new strategy for
improving success in chemotherapy [15].
Deregulation of miR-592 was previously reported in other tumors such as high-grade
uveal melanoma, renal cell carcinoma, colorectal carcinoma with unaffected mismatch
repair mechanisms, and gastric cancer. Direct interactions with genes involved in cell
migration, motility, development, and regulation of cell signaling have also been deci-
phered [16]. As can be seen, there are many aspects that indicate miR-592 with interest for
cancer aggressiveness biomarker and also for prognosis and therapeutics in patients with
renal cell carcinoma. An over-expression of miR-592 is suggested to promote proliferation,
migration, and invasion of renal cell carcinoma cells by targeting SPRY2 (gene related to
PI3K/AKT and MAPK/EPK signaling pathways) [17]. In PC, there are also data relating
miR-592 with aggressiveness in combination with ANPEP, miR-217, and miR-6715b [18].
MiR-375 has been included as one of the classical miRNAs’ biomarkers in PC. It has im-
portance in several points of the disease, such as clinical T-stage and bone metastasis,
distinguishing between PC patients versus controls, and even differentiating between
benign prostatic hyperplasia (BPH) in urinary and serum exosomes [19–21]. This miRNA
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has been included as one of the main points for regulating proliferation, metastasis, and
EMT in PC, and it has also been included with a significant down-regulation after radical
prostatectomy in urine extracellular vesicles (EVs), clarified urine, and blood plasma [22].
One of the first proposals for using circulating miRNAs for PC screening was focused
on the ratios of several miRNAs, such as miR-106a/miR-130b and miR-106a/miR-223,
ratios for discriminating localized PC versus BPH patients [23]. However, there are more
reasons suggesting the relevant role of miR-130b in PC, such as miR-130b/miR-301b with
clinical variables reporting positive correlations with malignancy, T-stage, residual tumor
status, and primary therapy outcome [24]. The role of this miRNA and tumorigenesis is
mainly described by its effect on the down-regulation of MMP2 (matrix metalloproteinase-
2), which has a suppressive effect on PC metastasis [25]. Moreover, recent data have
attributed a function as a therapeutic target in anti-angiogenesis treatment by the correlation
of miR-130b/TNF-α/NF-κB/VEGFA feedback loop with angiogenesis in PC [26].
MiR-141 has been suggested as one of the most interesting markers for PC diagnosis
and even treatment [27]. Recent publications discovered that exosomal miR-141-5p levels
showed a slight increase in PC patients, so it is included as a useful specific marker for
PC [28] or even to distinguish among PC and BPH [29].
However, it is also important to take into account the role of germline, somatic, or
epigenetic mutations as new, promising, molecular networks and signaling pathways
implicated in aggressive PC, such as STAT3, PTEN, ATM, AR, and P53 [30], or cfDNA
(cell free DNA) and exosome-RNA, as reliable sources of AR variants, and their combined
detection in liquid biopsy that predicts resistance to AR signaling inhibitors in PC [31].
In conclusion, the election of an effective biomarker for PC is controversial. Recent
computational analysis indicated that miRNAs’ biomarkers along with the associated
miRNA–mRNA relationships are good options for PC management and carcinogenic
deciphering [32]. For that reason, we focused this study, including a complete analysis
combining bioinformatics’ strategies and laboratory assays, to prove the role of miR-93-
5p, miR-23c, miR-210-3p, miR-221-3p, miR-592, miR-141, miR-375, and miR-130b in PC
aggressiveness and diagnosis.
2. Materials and Methods
2.1. Study Subjects
Samples from fresh tissue of 131 men with confirmed PC and 28 fresh tissue samples
of control patients were included in the present study. Subjects with prostate-specific
antigen (PSA) levels ≥4.0 ng/mL, meeting the criteria for undergoing a prostate biopsy,
were recruited from 2012 to 2014 and included in this study (Table 1). Samples classified as
controls were those with negative biopsy values. All individuals underwent a systematic,
20-core ultrasound-guided biopsy in order to limit the false-negative rates. Those with
positive biopsy for PC were analyzed for T stage, serum PSA levels, and Gleason score, and
then classified according to D’Amico risk classification (low, intermediate, and high risk).
Clinical follow-up for 60 months was performed by urologists from the “Hospital Virgen
de las Nieves, Granada, Spain”. Moreover, 60 plasmas from peripheral blood collected
in EDTA tubes, from the same men of the previously collected tissue samples, were also
included in the analysis for proving liquid biopsy biomarkers. Samples were collected and
stored at −80 ◦C until processing. All participants provided a written, informed consent,
and the study was previously approved by the Research Ethics Committee of Granada
Centre (CEI-Granada internal code 1638-N-18) following the Helsinki ethical declaration.
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Table 1. Descriptive characteristics of PC tissue samples (n = 131).
Variables Patients
Age average 69.11
Total Age range 48–88
PSA (prostate specific antigen) debut (ng/mL)
> 4 ≤ 10 72 (55.0%)



















The Cancer Genome Atlas (TCGA) was launched as one of the main projects accelerat-
ing the comprehensive understanding of the genetics of cancer using innovative genome
analysis technologies, helping to generate new cancer therapies, diagnostic methods, and
preventive strategies [33,34]. The structure of TCGA is well organized and involves several
cooperating centers responsible for collection and sample processing, followed by high-
throughput sequencing and sophisticated bioinformatics data analyses [35]. This makes
TCGA repositories extraordinary-value sources of data in studies of the characteristics of
the present work. By using prostate adenocarcinoma (PRAD) repository information from
TCGA Program, a miRNAs’ differential expression analysis was carried out to identify
differentially expressed miRNAs that could potentially serve as biomarkers.
2.2.1. TCGA Data of Prostate Adenocarcinoma (TCGA_PRAD)
A total of 531 isoforms’ expression quantification (miRNA-Seq) files containing tumor
(T; n = 480) and non-tumor (NT; n = 51) tissue samples, as well as clinical data for each
sample, were obtained from the TCGA data portal (https://portal.gdc.cancer.gov, accessed
on 04 June 2021). Out of the 480 T samples, 285 were from patients with Gleason score
≤7 (G1) and 195 corresponded to patients with Gleason score >7 (G2). The NT samples
were included in the G0 group.
2.2.2. Differential Expression (DE) Analysis
TCGA_PRAD differential expression analyses were carried out using edgeR (version
3.28.0) Bioconductor package [36,37]. The GLM (Generalized Linear Models) approach
was used to include an experimental design with Gleason score as factor. Quasi-likelihood
F-test (QL) was used to determine differentially expressed (DE) miRNAs related to tu-
mor aggressiveness. Three categories were defined: (1) G0 = NT samples (51 cases),
(2) G1 = Gleason score ≤ 7 (285 cases), and (3) G2 = Gleason score > 7 (195 cases). Lowly
expressed miRNAs (miRNAs that did not reach 1 count per million in a minimum of
51 samples) were filtered out. By using this filter, 1564 miRNAs were removed from the
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initial 2095. Samples were normalized by using the trimmed mean of M-values (TMM)
method [38]. Three contrasts were carried out in the analysis: G0 vs. G1, G0 vs. G2,
and G1 vs. G2. The p-value was adjusted by Benjamini–Hochberg false discovery rate
(FDR) procedure [39]. Differentially expressed miRNAs were those having a fold change
|FC ≥ 1.5| and a FDR < 0.05. Principal Component Analysis (PCA) algorithm [40] was
used for graphic representation of samples distribution based on DE miRNA by using the
M3C (version 1.8.0), ggrepel (version 0.8.1), and ggplot2 (version 3.0.1) packages in the
R environment.
2.3. Molecular Analysis
Total RNA of 159 fresh tissue biopsies were extracted using Trizol®/chloroform
method and quality validated by A260/A280 in NanoDrop™ 2000c (Thermo Fisher Sci-
entific, Inc., Wilmington, DE, USA). Reverse transcription was performed with TaqMan™
Advanced miRNA cDNA Synthesis kit (Applied Biosystem, Foster City, CA, USA). Quanti-
tative polymerase chain reaction (qPCR) was performed with TaqMan probes (Life Tech-
nologies, Carlsbad, CA, USA), according to the manufacturer’s protocol, on a 96-wells
plate with QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems). The qPCR
reactions were performed as follows: 5 ◦C during 20 s for enzyme activation, followed by
40 cycles of 1 s at 95 ◦C and 20 s at 60 ◦C for denaturing and annealing/extension. For the
liquid biopsy analysis, plasmas of 60 samples were isolated from blood. This process was
carried out, at most, 4 h after collection. Total RNA of the samples was extracted using the
miRNeasy Serum/Plasma Kit (GE; Qiagen, Hilden, Germany). All samples were run in
triplicates, with a NTC (non-template control) in each plate; Cts ≥ 35 was considered as
undetermined value.
2.4. Selection of Candidate miRNA Normalizers
First, we chose among previously published data the most effective housekeeping,
selecting GAPDH, RNU6B, and miR-130b as possible effective candidates. We analyzed
those displaying the highest stability and the lowest biological variance in PC. After
developing an assay of qPCR, as explained above, we analyzed the mean, standard de-
viation (SD), and variation coefficient (CV) comparing with Ct (see details in Table S1).
Moreover, to choose the best housekeeping we used several computational programs
such as NormFinder [41] (https://moma.dk/normfinder-software) and BestKeeper [42]
(http://www.gene-quantification.de/bestkeeper.html, accessed on 04 June 2021) to assure
the stability of endogenous housekeeping in PC (details in Table S2). Finally, RNU6B (Ct
mean = 29.446) was chosen by its higher stability in these samples (see details in Figure S1).
2.5. Selection of the MiRNAs
After combining bioinformatic analysis with the most appropriate miRNAs, according
to pubMed publications (including biomarkers, cancer aggressiveness, and PC), we finally
chose eight miRNAs for the experimental analysis in tissues and plasmas from peripheral
blood samples. From the bioinformatics reports, we selected DE miRNAs (see details in
Tables S2 and S3), and all those miRNAs in top position and with confirmed role in cancer
or PC development were selected. Therefore, miR-592, miR-23c, miR-93-5p, miR-210-3p,
miR-141, miR-375, miR-130b, and miR-221-3p (see Table S3) were included in the present
analysis. MiRNAs’ expression levels were quantified using the comparative threshold
cycle (Ct) method (2−∆∆Ct), relative to RNU6B expression as an endogenous control.
2.6. Statistical Analysis
SPSS v.22 (IBM Inc, Armonk, NY, USA) and GraphPad Prism v.5 software (Graph-
Pad Software Inc, La Jolla, CA, USA) were used for analysis and graphic designing. A
p value < 0.05 was considered as significant value. MiRNAs’ expression patterns’ com-
parisons were done using value 2−∆∆CT. Kolmogorov–Smirnov test was developed to
assess normal distribution of all data. For determining significant differences among
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A bioinformatic analysis using TCGA repository was developed to select the most
appropriate miRNAs in PC.
3.1.1. TCGA Data of Prostate Adenocarcinoma (TCGA_PRAD)
First, TCGA analysis reported several top miRNAs as up-regulated and down-regulated
with effect in PC aggressiveness according to Gleason Score. We developed two main
comparisons, selecting samples with reported paired results reported in a healthy area (G0)
of PC tissue and an affected tumor area, with Gleason scores equal to or below 7 (G1) and
above 7 (G2) (see details in Table 2), G0 vs. G1 and G0 vs. G2 (in Tables S4 and S5).
Table 2. Candidate miRNAs for prognosis biomarkers of PC (G1 vs. G2).
miRNA logFC F p Value FDR
miR-592 2.0006 150.59191 1.14192 × 10−30 6.06360 × 10−28
miR-508-3p −3.41187 135.34909 4.85900 × 10−28 1.29006 × 10−25
miR-210-3p 1.45741 109.56902 1.89422 × 10−23 3.35277 × 10−21
miR-514a-3p −2.66782 103.89153 2.06217 × 10−22 2.73753 × 10−20
miR-509-3p −2.73042 98.307609 2.20640 × 10−21 1.95267 × 10−19
miR-708-5p 0.72937 86.798789 3.13431 × 10−19 2.37759 × 10−17
miR-425-5p 0.58884 71.284172 2.93140 × 10−16 1.94571 × 10−14
miR-133b −0.92370 60.11197 4.56314 × 10−14 1.86386 × 10−12
miR-133a-3p −0.75474 55.654882 3.52380 × 10−13 1.24742 × 10−11
miR-217 0.79852 54.514827 5.96134 × 10−13 1.97842 × 10−11
miR-137 1.78649 51.939089 1.964050 × 10−12 5.79394 × 10−11
miR-653-5p 0.61648 50.472116 3.884013 × 10−12 1.08547 × 10−10
miR-221-5p −1.00961 46.700419 2.263673 × 10−11 5.46368 × 10−10
miR-7641 −1.33368 44.875201 5.339282 × 10−11 1.23267 × 10−9
miR-1-3p −0.59135 43.944679 8.280247 × 10−11 1.75872 × 10−9
miR-6715b-3p −1.23979 40.649659 3.944519 × 10−10 7.48050× 10−9
miR-301a-5p 0.64561 40.571194 4.094489 × 10−10 7.49715 × 10−9
miR-129-5p 0.92748 38.07787 1.344876 × 10−9 2.23165 × 10−8
miR-4449 −1.28009 36.42357 2.971930 × 10−9 4.64145 × 10−8
miR-216a-5p 0.82891 35.55502 4.512166 × 10−9 6.84560 × 10−8
miR-5680 0.76444 34.34927 8.068259 × 10−9 1.19006 × 10−7
miR-449a 1.20256 29.54196 8.334028 × 10−8 1.02915 × 10−6
miR-23c −0.90493 28.19839 1.609267 × 10−7 1.81812 × 10−6
miR-1298-5p 1.10526 27.73253 2.022880 × 10−7 2.23781 × 10−6
miR-378d −0.61904 25.98869 4.775705 × 10−7 4.69611 × 10−6
Summary reports of miRNAs: down-regulated, 17; up-regulated, 16; total DE miRNAs, 33. Abbreviations: DE
(differential expression); logFC (logarithmic fold change); F (quasi-likelihood F-statistic for the GLM (quasi-
likelihood F-test)); FDR (False Discovery Rate). Here, comparisons were developed, including tissue samples (480
cases), comparing tumoral area below Gleason ≤7 (G1; n = 285) with tumoral tissue area above Gleason >7 (G2;
n = 195).
Sampl−s were analyzed with PCA, and a clear difference among non-tumoral (G0)
versus tumoral (G1 and G2) was denoted. However, not many dispersions of the data were
remarked among Gleason score equal to or below 7 (G1) compared to those above 7 (G2).
As can be seen, the majority G1 samples were closer to G0 (more details in Figure 1).
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3.1.2. Differential Expression (DE) Analyses
When performing DE analysis, we found that 9.7% of all miRNAs were in common
when comparing non-tumoral vs. tumoral samples. Therefore, these miRNAs could be
common pathways in prostate. The highest differences were found when comparing non-
tumoral (G0) versus tumoral samples with Gleason scores above 7 (G2) (more details in
Figure 2).
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Volcano plots (Figure 3) represent miRNAs’ dispersion according to their expression
patterns, using logFC (X axis) versus statistical significance FDR (Y axis). Blue represents
those miRNAs that are not differentially expressed contrasting with DE analysis, which is
represented in red. Nearer to the left side are miRNAs under-expressed contrasting with
those closer to the right side, which are over-expressed. Moreover, those miRNAs that are
on the upper part of the Y axis had a stronger statistical significance. The most interesting
miRNAs for the present work are identified as surrounded by a circle in Figure 3. We have
also represented, using volcano plots, both comparisons, G0 versus G1 and G0 versus G2
(see details in Figures S2 and S3).
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3.2. olecular Analysis
Those miRNAs with stronger evidence in PC, according to publications and previously
described bioinformatic analyses, were then validated in a cohort of 159 fresh tissue samples
(see details in Table 1) and 60 plasma samples. Although some of these miRNAs, such
as miR-141, miR-375, and miR-130b, did not have relevant positions according to our
bioinformatic analysis, we just included them for having over-expressed values with low
log-FDR (see Table 2, Tables S2 and S3, Figure 3, Figures S2 and S3). By contrast, these
are some of the most significant miRNAs according to previous publications [19,24,43–45].
Therefore, we decided to include them in the validation process by doing laboratory
experiments. However, we could not find any significant statistical value when comparing
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with clinical parameters such as PSA, Gleason score, T stage, and D’Amico risk (more
details in Figures S4 and S5).
As can be seen in Figure 4, the expression trend in both studies, with our cohort and
TCGA data, is the same for all miRNAs, except for miR-212-3p and miR-23c. According to
the remaining miRNAs selected based on TCGA analysis, we developed two main clusters.
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Figure 4. rt of di ferential expre sion from qPCR versus TCGA d ta. (a) Plot showing
differentially expressed miRNAs when comparing in TCGA (RPKM: Reads per Kilobase Million.
* The values expressed in miR-141 and 130b include both -3p and -5p, to be able to compare with the
qPCR results. (b) Plot showing differentially expressed miRNAs when comparing in qPCR analysis.
One included miR-210-3p, miR-23c, and miR-592, which had concordance in experi-
mental and bioinfor atic analysis. All these three miRNAs demonstrated an interesting
value as PC ggressiveness biomarkers (G1 vs. G2 comparisons). When comparing bioin-
formatic data (TCGA) in our analysis with those data from qPCR, miR-210-3p showed a
high expression pattern in G2 vs. G1 (p = 1.89 × 10−23). This patte n was also aintained
in qPCR data in biopsy sam les (p = 0.001). In the case of miR-23c and miR-592, the ame
express on patterns were also foll wed in G1 and G2, but with no stati tically signific t
values (detail in Table S6). Surprisingly, when c mparing 0 vs. 1 and G0 vs. G2
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we found in miR-23c a great change in TCGA analysis versus qPCR in tissue samples.
Moreover, miR-592 could be a follow-up biomarker because it had the same tendency in
TCGA and in qPCR analysis, but its low expression made it difficult to obtain plasmas
from peripheral blood characterization.
Secondly, miRNA 93-5p showed the same patterns in bioinformatic (TCGA) and
experimental analysis (qPCR) in all comparisons (G1 vs. G2) (see details in Figure 4 and
Figure S6). Moreover, miR-93-5p and 210-3p were the ones with the most statistically
significant as diagnostic biomarkers (more details in Table S6).
Moreover, when trying to find the most suitable biomarker for liquid biopsy, we
believed that miR-93-5p was the best choice. As we have previously mentioned, it followed
the same patterns in all analyses (TCGA and qPCR) and in all samples (plasmas from
peripheral blood and tissues), and it had statistically significant values in most of the
analysis (Table S6) (more details in Figure S6).
3.3. Predicted Functional Analysis
In order to identify potential target genes for miRNAs associated with aggressiveness
and diagnosis (miR-210-3p, miR-23c, miR-592, and 93-5p), we performed an integrated
target prediction using two different databases: Mirtarbase (http://mirtarbase.cuhk.edu.
cn, accessed on 04 June 2021) and MiRWalk3.0 (http://mirwalk.umm.uni-heidelberg.de,
accessed on 04 June 2021). The miRNA target genes indicated by both prediction programs,
especially those related to carcinogenic processes, were identified.
In a subsequent analysis using IPA (Ingenuity Pathway Analysis) [46], STRING
(https://string-db.org/) [47], and DAVID Bioinformatics Resources v6.8 (https://david.
ncifcrf.gov, accessed on 04 June 2021) [48], we obtained the role of gene set, clinical impli-
cation, ontology, and involved metabolic pathways. As a result of this approach, we were
able to identify two target genes for miR-93-5p (i.e., STAT3 and IGF2) that may be involved
in the development and progression of PC (Figure 5). Thus, we focused the functional
analysis on both genes to see pathways’ interactions (more details in Figure S7).
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4. Discussion
Looking for efficient biomarkers for PC diagnosis and stratification is one of the most
important gaps between research and medicine in managing PC. Diagnostic, monitoring,
and prognosis biomarkers in PC are still well undefined. There is much research focusing
on looking for a stable molecule that could help in PC management. MiRNAs’ profiling
has shown important results, such as the use of miRNAs present in semen exosomes
(miR-142-3p, miR-142-5p, and miR-223-3p) as models based on molecular biomarkers for
improving PC diagnosis/prognosis efficiency [49] as well as the use of miR-17, miR-20a,
miR-20b, and miR-106a signatures in blood that can distinguish high- and low-risk PC
patients after radical prostatectomy [50] or urinary exosomes’ microRNAs (miR-196a-5p
and miR-501-3p) as non-invasive biomarkers [51]. The stability of miRNAs, combined
with the increased range of methodologies for their study and their key role in several
regulatory pathways such as EMT, angiogenesis, metastasis, and drug resistance [52],
makes miRNAs one of the most promising options as biomarkers in PC. It is true that most
of the research is focused on miRNAs. Nevertheless, they are not the unique, non-invasive
biomarkers being currently studied. Others, such as neutrophil-to-lymphocyte ratio [53],
DLX1, PCA3, and DUOX1 mRNA plasma expressions [54] or a 14-genes’ panel urine test
including PMP22, GOLM1, LMTK2, EZH2, GSTP1, PCA3, VEGFA, CST3, PTEN, PIP5K1A,
CDK1, TMPRSS2, ANXA3, and CCND1 [55], are some of the most updated research in PC
non-invasive biomarkers. However, as previously mentioned by several authors, such as
H.P. Liu et al., miRNAs are suitable molecules for being biomarkers in PC with sensitivity,
specificity, and accuracy values next to 99% in extended cohorts [56].
It is true that liquid biopsy is one of the main focuses of attention in current research,
with the aim to apply it to the biomedical field. It is known that, compared to tissue
samples, liquid biopsies are of particular interest in clinical settings due to their minimal
invasiveness since they provide the opportunity to repeat sampling, as well as to have a
whole representation of the entire tumor [57]. Liquid biopsies could be a relevant point
when there is limited access to the tissue biopsy, giving increasing advantages in precision
medicine for direct biomarker application in clinical practice [58]. Moreover, PC is a
heterogeneous tumor and there are discrepancies in published data. Therefore, a deep
analysis combining bioinformatics and molecular experimental analysis could be the clue
to improve the use of miRNAs as biomarkers in PC.
Present bioinformatics analysis gave us results of major miRNAs, such as miR-891a-
5p, miR-23c, miR-93-5p, miR-145-3p, and miR-221-3p, when comparing NT versus T
values with Gleason score above 7, or miR-592, miR-508-3p, miR-210-3p, miR-514a-3p, and
miR-509-3p, when comparing G1 vs. G2 in tumoral samples. However, not all of them
have been pointed out with a relevant role in PC or tumorigenesis effect, such as miR-
891a-5p, miR-145-3p, miR-508-3p, miR-514a-3p, or miR-509-3p, which were discarded in
subsequent molecular analysis. The remaining miRNAs were selected with a strong relation
in publications and bioinformatics analysis in PC or tumor aggressiveness. However,
several miRNAs, such as miR-141, miR-375, and miR-130b, lost interest as biomarkers when
performing expression analysis in the present study because there were no differences
among PC risk or even prognosis. Nevertheless, when looking in literature, these are
among the most highlighted miRNAs as suitable biomarkers in urine, for PC diagnosis
and progression [19,21]; in plasma, for time to progression of metastatic castration-resistant
PC or biomarker screening [20,23,24,59]; or even associated with an increased risk of
biochemical recurrence [60]. By contrast, when studying them in the present bioinformatics
analyses, these three miRNAs (141, 375, and 130b) completely lost total statistical power
(Figures 3 and 4).
When comparing the remaining potential miRNAs, according to the present bioin-
formatics analysis (miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, and miR-592), all were
suggested with important roles in PC screening [61], aggressiveness [8,62,63], and recur-
rence [7,18,64], or even new etiological values [65] were suggested. These miRNAs have
also been highlighted with carcinogenic effects in other tumors, such as endometrial [66,67],
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osteosarcoma [68], hepatocellular [69], renal [17,70], or colorectal [71], among others [72–74].
According to our experimental analysis, miR-210-3p, miR-23c, and miR-592 were suggested
as aggressiveness biomarkers in PC and miR-93-5p, miR-130b, and miR-141 were suggested
as diagnostic biomarkers for this tumor.
Moreover, if we try to develop non-invasive biomarkers, we will select miR-93-5p
for diagnostic purposes, according to the obtained data in TCGA, and analysis in tissue
and plasmas from peripheral blood samples. MiR-210-3p and 592 should also be good
options. Even though the obtained results in plasmas from peripheral blood samples of
the present study were scarce, TCGA and tissue analysis showed relevant data. Although
we know that one of the limitations of the present study is the small amount of plasma
from peripheral blood samples included in these experiments, it is certain that the same
tendency was shown in all of the present samples, which allows us to encourage the role
of non-invasive biomarkers and to face future analysis in liquid body samples. Moreover,
previously published data indicated the promising role of miR-93-5p for predicting the dis-
ease aggressiveness with diagnosis accuracy in liquid biopsy [75] or even associated with
lymphatic dissemination [66]. Here, we reinforced the role of miR-93-5p as a biomarker
in PC because all present analyses (bioinformatics and experimental) showed the same
patterns. Moreover, it was related to IGF2 and STAT3 genes, according to the integrated
target prediction. Both genes have proven oncogenic effects, such as the role of acetylated
STAT3-mediated activation of IGF2 transcription in HDI (Histone deacetylase inhibitors)
resistance described in NSCLC (non-small-cell lung carcinoma) [76]. There are also some
reports in PC. Furthermore, the role of IGF2 messenger RNA binding protein 3 (IMP3)
produces an acceleration in PC progression through activating PI3K/AKT/mTOR signaling
pathway via increasing SMURF1-mediated PTEN ubiquitination [77]. All these data rein-
force our results about the promising use of miR-93-5p as PC biomarkers. It was previously
only suggested by bioinformatics analysis in the study of Y. Yang et al. [78]. Moreover, miR-
93-5p in hepatocellular carcinoma has been proven to bind to the 3′-untranslated region
(UTR) of mitogen-activated protein kinase kinase kinase 2 (MAP3K2). MAP3K2 directly
up-regulated its expression and down-regulated p38 and c-Jun N-terminal kinase (JNK)
pathway. All these pathway connections lead to cell cycle progression in hepatocellular
carcinoma and also explain its possible role in PC [79]. Moreover, it has been described that
AHNAK is the target gene of miR-93-5p. This gene is a large, scaffolding protein, which has
also been identified as acting as a tumor suppressor and which is highly related to tumor
metastasis. It has been suggested that AHNAK plays an inhibitor role in migration and
invasion, as well as EMT in cancer [80]. Therefore, we hypothesized that miR-93-5p may
also be involved in migration and invasion or EMT process in PC, as it has been described
in gastric, hepatocellular, and NSCLC cancer. It was previously suggested by Yang K et al.,
who indicated that miR-93 would function as a tumor promoter in PC by targeting disabled
homolog 2, and Liu JJ et al., who found that miR-93 could promote the proliferation and
invasion of PC cells by upregulating their target genes TGFBR2, ITGB8, and LATS2 [81].
By contrast, there is just one publication that indicated the role of miR-23c in PC,
suggesting its role in dormancy [8]. Other reports suggest this miRNA has a role as
a therapeutic target in ovarian cancer [68] and implicate the molecular regulation of
endometrial or hepatocellular cancers [66,69]. According to KEGG Pathways, miR-23
up-regulates MAPK1 and FGFR3 genes in bladder cancer. Both these genes have been
seen in many cancers at different stages, such as proliferation, by interactions with RAS-
MAPK pathways. These genes are confirmed for having an oncogenic potential role across
multiple cancer types; indeed, MAPK1 is altered in 0.82% of all cancers [82]. Although in
PC there are scarce data about the role of miR-23c, it makes sense what we have proven
in the present article concerning its role as biomarker for aggressiveness. According to
the Atlas of Genetics and Cytogenetics in Oncology and Haematology, in prostate tumors
the level of activated MAP kinase was increased with higher Gleason score and tumor
stage, while non-neoplastic prostate tissue showed little or no staining with activated MAP
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kinase antiserum, which makes sense with the miR-23 c correlation in PC in the present
report [83].
The remaining suggested biomarkers in the present study, such as miR-210-3p, have
been previously reported in relation to activating the NF-κB signaling pathway in PC [11]
and miR-592 distinguishing between T2c to T3b PC stages [18]. The present data, although
they are scarce, are in the same line with previous reports, linking these miRNAs with PC
aggressive stages.
The novelty of the present work is that it gives strong associations using three different
strategies (bioinformatics and expression analysis in tissue samples and in plasma samples),
providing a correlation between these analysis in miRNAs and PC.
5. Conclusions
In summary, our study is one of the first reports combining bioinformatics and exper-
imental analysis (in plasma and tissue PC samples) for validating miR-210-3p, miR-23c,
miR-93-5p, and miR-592 as promising biomarkers in PC. According to our results, we will
suggest that miR93-5p is the most promising non-invasive biomarker for PC aggressiveness
and diagnosis. This is the first time that miR-23c has been related to PC. Future analysis in
these miRNAs, using more samples of plasmas from peripheral blood and urine, could
be one of the most important steps for finally including these miRNAs as non-invasive
biomarkers for precision medicine in PC.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/biomedicines9060646/s1. Supplementary Figure S1: Selection of candidate miRNA normalizer
assay. Supplementary Figure S2: Volcano Plot comparing non-tumoral samples (G0) with tumoral
samples with Gleason score > 7 (G1). Supplementary Figure S3: Volcano Plot comparing non-
tumoral samples (G0) with tumoral samples with Gleason score > 7 (G2). Supplementary Figure S4:
Expression patterns of miRNAs (141, 375, and 130b). Supplementary Figure S5: Expression patterns
of miRNAs (141, 375, and 130b), according to PSA values, ranged from >4 to <10 ng/mL, >10 to
<20 ng/mL, and >20 ng/mL. Supplementary Figure S6: MiRNA 93-5p expression patterns in tissue
and plasma using 2−∆Ct normalization with RNU6B. Supplementary Figure S7: Pathways’ interaction
IGF2 and STAT3. Supplementary Table 1: Values obtained for selection of the best housekeeping.
Supplementary Table 2: Reported data of housekeepings, according NormFinder and BestKeeper
tools. Supplementary Table S3: Details of the probes. Supplementary Table S4: Candidate miRNAs
for diagnostic biomarkers of PC (G0 vs. G1). Supplementary Table S5: Candidate miRNAs for
diagnostic biomarkers of PC (G0 vs. G2). Supplementary Table S6: Comparisons’ values between
TCGA and qPCR analysis developed in biopsy and plasmas from peripheral blood.
Author Contributions: Conceptualization, L.J.M.-G. and M.J.A.-C.; methodology, I.R.-F., A.A.-R. and
J.M.G.-C.; formal analysis, L.J.M.-G., V.S.-C. and M.J.A.-C.; investigation, I.R.-F., V.S.-C., E.A.-L. and
J.M.G.-C.; resources, F.V.-A. and J.A.L.; data curation, E.A.-L. and J.M.G.-C.; writing—original draft
preparation, L.J.M.-G. and M.J.A.-C.; writing—review and editing, L.J.M.-G. and M.J.A.-C.; supervi-
sion, L.J.M.-G. and M.J.A.-C.; project administration, J.A.L. and F.V.-A.; funding acquisition, J.A.L.,
L.J.M.-G. and M.J.A.-C. All authors have read and agreed to the published version of the manuscript.
Funding: This project was partially funded by Regional Ministry of Health and Families of the
Andalusian Government (ref: PI-0319-2018) and managed by FIBAO (Andalusian Public Foundation
for Biomedical Research in Eastern Andalusia, “Alejandro Otero”).
Institutional Review Board Statement: This project was evaluated by CEI-Granada (Committee
Ethical Institution of Granada) and approved with the internal code 1638-N-18.
Informed Consent Statement: The study protocol was approved by the institutional ethics commit-
tee, CEI-Granada, and was conducted in accordance with the Declaration of Helsinki.
Data Availability Statement: The data that support the findings of this study are available from the
corresponding author under reasonable request from L.J.M.-G. and M.J.A.-C.
Biomedicines 2021, 9, 646 14 of 17
Acknowledgments: We want to thank all donors who made this study possible. Present published
results are a part of the PhD thesis of the candidate Victor Sanchez Conde in the Biomedicine Doctoral
Program of the University of Granada. Finally, we would like to thank TCGA Research Network
because parts of the results are based on data generated from this project.
Conflicts of Interest: There are no conflict of interest to declare.
References
1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef]
2. Huang, Z.; Sun, Y.; Chen, G.; Dang, Y.; Lu, H.; He, J.; Cheng, J.; He, M.; Li, S. MiRNA-145-5p expression and prospective molecular
mechanisms in the metastasis of prostate cancer. IET Syst. Biol. 2021, 15, 1–13. [CrossRef]
3. Yu, W.; Hurley, J.; Roberts, D.; Chakrabortty, S.; Enderle, D.; Noerholm, M.; Breakefield, X.; Skog, J. Exosome-based liquid biopsies
in cancer: Opportunities and challenges. Ann. Oncol. 2021, 32, 466–477. [CrossRef]
4. Tao, L.; Pan, X.; Wang, J.; Zhang, L.; Tao, L.; Liang, C. Circular RNA circANKS1B acts as a sponge for miR-152-3p and promotes
prostate cancer progression by upregulating TGF-α expression. Prostate 2021, 81, 271–278. [CrossRef]
5. Sun, X.-B.; Chen, Y.-W.; Yao, Q.-S.; Chen, X.-H.; He, M.; Chen, C.-B.; Yang, Y.; Gong, X.-X.; Huang, L. MicroRNA-144 Suppresses
Prostate Cancer Growth and Metastasis by Targeting EZH2. Technol. Cancer Res. Treat. 2021, 20, 1533033821989817. [CrossRef]
[PubMed]
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